ENTITY

Oryzon Genomics (ORY SM)

58
Analysis
Health CareSpain
Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.
more
bullishOryzon Genomics
14 Mar 2023 15:38Issuer-paid

Oryzon Genomics - New clinical candidate expands CNS portfolio

Oryzon Genomics has nominated a new central nervous system (CNS) clinical development candidate, ORY-4001, for the treatment of rare CNS disorders...

Share
bullishOryzon Genomics
06 Mar 2023 23:34Issuer-paid

Oryzon Genomics - Catalysts on the horizon in FY23

FY23 is shaping up to be a busy clinical year for Oryzon with readouts and trial initiations expected across its lead assets. The next major...

Share
bullishOryzon Genomics
28 Feb 2023 20:36Issuer-paid

Oryzon Genomics - KOL event puts near-term catalysts in the spotlight

At Oryzon’s recent key opinion leader (KOL) event, management elaborated on the near-term clinical catalysts for its lead assets iadademstat, in...

Share
bullishOryzon Genomics
21 Feb 2023 15:06Issuer-paid

Oryzon Genomics - Progress in oncology and CNS in FY22

Oryzon Genomics has presented headline FY22 financial results, which reflect continued progress on its clinical activities for key assets...

Share
bullishOryzon Genomics
19 Jan 2023 00:20Issuer-paid

Oryzon Genomics - First Phase II patient enrolled is clinical milestone

Oryzon Genomics has announced that it has enrolled the first patient into its collaborative Phase II trial investigating the use of its lead LSD1...

Share
x